Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

Neuro-Oncology

Volumn 11, Issue 6, 2009, Pages 747-756

  Maurer, Gabriele D ^a,b   Tritschler, Isabel ^a   Adams, Barbara ^a   Tabatabai, Ghazaleh ^a   Wick, Wolfgang ^c   Stupp, Roger ^d   Weller, Michael ^a,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chemotherapy; Cilengitide; Glioma; Integrin; Temozolomide

Indexed keywords

ALPHAVBETA5 INTEGRIN; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CILENGITIDE; CYTOKINE RESPONSE MODIFIER A; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN BCL XL; PROTEIN P53; TEMOZOLOMIDE; VITRONECTIN RECEPTOR;

ARTICLE; CELL ADHESION; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE SILENCING; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; METHYLATION; PROTEIN EXPRESSION; RADIOSENSITIVITY;

EID: 73249136703     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2009-012     Document Type: Article

References (38)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Stupp R, Hegi Me, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180.
3. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir eG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046-1069.
4. Goldbrunner RH, Bernstein JJ, Tonn JC. eCM-mediated glioma cell invasion. Microsc Res Tech. 1998;43:250-257.
5. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816-826.
6. Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas. Front Biosci. 1999;4:D188-D199.
7. Bogler O, Mikkelsen T. Angiogenesis and apoptosis in glioma: two arenas for promising new therapies. J Cell Biochem. 2005;96:16-24.
8. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v) beta5 integrin expression in glioma periphery. Neurosurgery. 2001; 49:380-390.
9. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci. 1995;108(pt 3):947-956.
10. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991;88:1924-1932.
11. Mattern RH, Read SB, Pierschbacher MD, et al. Glioma cell integrin expression and their interactions with integrin antagonists: research article. Cancer Ther. 2005;3A:325-A340.
12. Gladson CL. expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol. 1996;55:1143-1149.
13. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs. 2003;4:722-731.
14. Maubant S, Saint-Dizier D, Boutillon M, et al. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood. 2006;108:3035-3044.
15. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13:555-562.
16. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res. 1999;5:1587-1594.
17. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25:1651-1657.
18. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610-5617.
19. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (eMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2007;25:2000.
20. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008;17:1225-1235.
21. Dechantsreiter MA, Planker e, Matha B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999;42:3033-3040.
22. Weller M, Rieger J, Grimmel C, et al. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer. 1998;79:640-644.
23. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/ CDKN2A, p14ARF, PTeN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9:469-479.
24. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 2003;22:8233-8245.
25. Glaser T, Wagenknecht B, Weller M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene. 2001;20:4757-4767.
26. Wagenknecht B, Schulz JB, Gulbins e, Weller M. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Differ. 1998;5:894-900.
27. Hermisson M, Klumpp A, Wick W, et al. O6-Methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96:766-776.
28. Bähr O, Rieger J, Duffner F, et al. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol. 2003;13:482-494.
29. Naumann U, Kügler S, Wolburg H, et al. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res. 2001;61:5833-5842.
30. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296: 550-553.
31. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239-3245.
32. Albini A, Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc. 2007;2:504-511.
33. de la Monte SM, Lahousse SA, Carter J, Wands JR. ATP luminescencebased motility-invasion assay. Biotechniques. 2002;33:98-100, 102, 104 passim.
34. Webb J. effects of more than one inhibitor. In: Webb JL, ed. Enzymes and Metabolic Inhibitors. Vol. 1. New York: Academic Press; 1963: 487-512.
35. Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg. 2001;94:978-984.
36. Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer. 2003;89:2122-2132.
37. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007;1775:163-180.
38. Hegi Me, Diserens AC, Gorlia T, et al. MGMT gene silencing and bene-fit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.